FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to use of a derivative containing C-O-P bonds in the form of a controlled-release dosage form for treating patients with renal insufficiency. Invention also includes use of said derivatives together with other active substances, which, in particular, can be selected from a group, comprising a calcimimetic, a vitamin, a phosphate-binding preparation, thiosulphate, bisphosphonate, pyrophosphate, citrate, a diuretic, an antihypertensive agent and an anti-cholesteremia agent.
EFFECT: what is presented is using derivatives containing C-O-P compounds in patients with renal insufficiency.
13 cl, 12 ex, 14 dwg
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION, CONTAINING CRYSTALLISATION-INHIBITING SUBSTANCES | 2009 |
|
RU2535094C2 |
AGENT FOR LOW-TURNOVER METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2491940C1 |
AGENT FOR LOW-METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2485957C1 |
COMPOSITION CONTAINING CRYSTALLIZATION INHIBITORS | 2014 |
|
RU2691060C2 |
METHOD FOR MODELING ELECTROLYTIC NEPHROPATHY IN RATS | 2003 |
|
RU2256953C2 |
COMPOSITE "VITALIZIN-1" FOR PROPHYLAXIS OF ATHEROSCLEROSIS, CARDIOVASCULAR DISEASES AND MAINTAINING THERAPY IN VIRAL DISEASES | 2002 |
|
RU2217141C1 |
METHOD FOR REHABILITATION OF PATIENTS WITH RENAL DISEASE | 1999 |
|
RU2177324C2 |
METHOD FOR CORRECTION VASCULAR MICROELEMENT OVERSAVING ACCOMPANYING ATHEROSCLEROSIS | 2012 |
|
RU2510285C1 |
METHOD FOR PREVENTION OF TOXIC ACTION OF CADMIUM IN EXPERIMENTAL ANIMALS SUFFERING CHRONIC POISONING | 2011 |
|
RU2462764C1 |
COMPOSITE "VITALIZIN-2" FOR PROPHYLAXIS OF ATHEROSCLEROSIS, CARDIOVASCULAR DISEASES AND MAINTAINING THERAPY IN VIRAL DISEASES | 2002 |
|
RU2217138C1 |
Authors
Dates
2020-07-03—Published
2014-03-14—Filed